Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Wall Street Loses Faith in PayPal’s Near-Term Prospects

Robert Sasse by Robert Sasse
January 6, 2026
in Analysis, E-Commerce, Market Commentary, Nasdaq, Tech & Software
0
PayPal Stock
0
SHARES
40
VIEWS
Share on FacebookShare on Twitter

PayPal Holdings, Inc. is entering the new year facing a notable retreat in support from major financial institutions. A cluster of prominent investment banks have downgraded their outlooks for the digital payments company in a short span, citing concerns over weakening U.S. consumer spending and its direct impact on transaction volumes.

A Wave of Downgrades Hits the Stock

This pessimistic shift culminated on January 5, when Monness Crespi Hardt lowered its rating from “Buy” to “Neutral.” This move followed a series of similar actions by other heavyweight analysts in recent weeks:

  • JPMorgan issued a “Sell” recommendation on December 4, setting a price target of $70.
  • Bank of America downgraded the stock to “Neutral” on December 11, with a $68 target.
  • Morgan Stanley cut its rating to “Underweight” on December 18, projecting a share price of $51.

Citi analyst Bryan Keane maintained a “Hold” stance on January 5, but his price target of $60 offers minimal upside from the current trading level near $59.40, underscoring the widespread caution.

Institutional and Insider Selling Adds Pressure

The bearish sentiment extends beyond analyst notes. D.A. Davidson & Co. significantly reduced its stake, selling 66,407 shares in the third quarter—a cut of nearly 25%. This institutional selling was mirrored by activity within the company; corporate insiders disposed of more than 36,000 shares over the last three months.

Should investors sell immediately? Or is it worth buying PayPal?

Historically Cheap Valuation Fails to Attract Buyers

Despite the sell-off, PayPal’s fundamental metrics appear inexpensive. The stock trades at a price-to-earnings (P/E) ratio of just under 12, a level substantially below its historical average and far removed from the multiples above 20 common among other technology stocks. The business remains profitable, generating revenue of $32.91 billion and a net income of $4.92 per share.

However, the market is interpreting this low valuation as a warning sign rather than an opportunity. Shares are hovering close to their 52-week low of $55.85 and have declined approximately 30% year-over-year. Investors seemingly lack confidence in PayPal’s ability to sustain growth within the intensely competitive digital payments landscape.

All Eyes on the February Earnings Report

The company’s upcoming quarterly report, scheduled for February 3, 2026, is viewed as a critical test. It will reveal whether the current pessimistic analyst forecasts for 2026 are justified. Unless PayPal’s results and forward guidance deliver a positive surprise, the $60 price level is expected to act as a firm resistance point. The technical picture reinforces this downtrend, with the stock trading below both its 50-day moving average ($62.70) and its 200-day moving average ($67.81).

Ad

PayPal Stock: Buy or Sell?! New PayPal Analysis from March 25 delivers the answer:

The latest PayPal figures speak for themselves: Urgent action needed for PayPal investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

PayPal: Buy or sell? Read more here...

Tags: PayPal
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026
Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock
AI & Quantum Computing

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
Next Post
Intel Stock

Intel Stock Gains Momentum on Key Product Launch and Analyst Upgrade

FS KKR Capital Stock

FS KKR Capital Shares Face Persistent Selling Pressure

ASML Stock

ASML Shares Surge to Record High Amid Semiconductor Boom

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com